Dianthus Therapeutics Statistics
Total Valuation
DNTH has a market cap or net worth of $1.56 billion. The enterprise value is $1.15 billion.
Important Dates
The last earnings date was Wednesday, November 5, 2025, after market close.
| Earnings Date | Nov 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
DNTH has 42.88 million shares outstanding. The number of shares has increased by 28.44% in one year.
| Current Share Class | 42.88M |
| Shares Outstanding | 42.88M |
| Shares Change (YoY) | +28.44% |
| Shares Change (QoQ) | +5.50% |
| Owned by Insiders (%) | 0.15% |
| Owned by Institutions (%) | 58.72% |
| Float | 18.97M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 505.37 |
| Forward PS | 975.30 |
| PB Ratio | 2.85 |
| P/TBV Ratio | 2.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 374.99 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 17.35, with a Debt / Equity ratio of 0.00.
| Current Ratio | 17.35 |
| Quick Ratio | 17.09 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -28.57% and return on invested capital (ROIC) is -19.80%.
| Return on Equity (ROE) | -28.57% |
| Return on Assets (ROA) | -18.82% |
| Return on Invested Capital (ROIC) | -19.80% |
| Return on Capital Employed (ROCE) | -25.35% |
| Revenue Per Employee | $39,462 |
| Profits Per Employee | -$1.62M |
| Employee Count | 78 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +23.60% in the last 52 weeks. The beta is 1.33, so DNTH's price volatility has been higher than the market average.
| Beta (5Y) | 1.33 |
| 52-Week Price Change | +23.60% |
| 50-Day Moving Average | 34.64 |
| 200-Day Moving Average | 23.89 |
| Relative Strength Index (RSI) | 59.10 |
| Average Volume (20 Days) | 504,971 |
Short Selling Information
The latest short interest is 3.74 million, so 8.73% of the outstanding shares have been sold short.
| Short Interest | 3.74M |
| Short Previous Month | 4.96M |
| Short % of Shares Out | 8.73% |
| Short % of Float | 19.74% |
| Short Ratio (days to cover) | 5.42 |
Income Statement
In the last 12 months, DNTH had revenue of $3.08 million and -$126.35 million in losses. Loss per share was -$3.49.
| Revenue | 3.08M |
| Gross Profit | 3.08M |
| Operating Income | -140.31M |
| Pretax Income | -126.35M |
| Net Income | -126.35M |
| EBITDA | -140.20M |
| EBIT | -140.31M |
| Loss Per Share | -$3.49 |
Full Income StatementBalance Sheet
The company has $402.61 million in cash and $1.29 million in debt, giving a net cash position of $401.33 million or $9.36 per share.
| Cash & Cash Equivalents | 402.61M |
| Total Debt | 1.29M |
| Net Cash | 401.33M |
| Net Cash Per Share | $9.36 |
| Equity (Book Value) | 546.45M |
| Book Value Per Share | 12.75 |
| Working Capital | 389.97M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$109.52 million and capital expenditures -$106,000, giving a free cash flow of -$109.63 million.
| Operating Cash Flow | -109.52M |
| Capital Expenditures | -106,000 |
| Free Cash Flow | -109.63M |
| FCF Per Share | -$2.56 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -4,558.41% |
| Pretax Margin | -4,104.78% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DNTH does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -28.44% |
| Shareholder Yield | -28.44% |
| Earnings Yield | -8.12% |
| FCF Yield | -7.05% |
Analyst Forecast
The average price target for DNTH is $65.44, which is 80.03% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $65.44 |
| Price Target Difference | 80.03% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 94.02% |
| EPS Growth Forecast (5Y) | 14.63% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
